Kristen Harrington-Smith discusses her work as Vice President and Head of CAR-T US at Novartis Oncology.

Team uncovers a potential therapeutic approach for patients deficient in a protein called Shank3.

The modernization and miniaturization of pharmaceutical production could expand the range of ingredients medicinal chemists use to make new drugs.

Immunotherapy for cancer is on the brink of breakthroughs. Learn how NIBR have high expectations for this medical science.

An interview with Thierry Diagana, Head of the Novartis Institute for Tropical Diseases.

A Novartis experimental drug in clinical trial aims to block liver cancer growth

Novartis immunologist describes the excitement of discovering a promising new immuno-oncology (IO) target in the treatment of acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).